Onco Actu du 4 septembre 2015

	2.6 Etiologie - Environnement
Could mobile devices raise skin cancer risk? [Reuters] Devices like tablets, smartphones and laptops can reflect ultraviolet light from the sun and may indirectly increase users' exposure to the cancer-causing wavelengths, according to a new study.
	3. Prévention
A Family Affair: Breast Cancer Prevention for Mothers, Daughters, and Women of All Ages [CANCER RESEARCH Catalyst] “TOGETHER – Every Woman’s Guide to Preventing Breast Cancer” provides background information on the disease, helps women put risk in perspective, and provides practical prevention tips for adults, including parents and grandparents who want to guide the girls in their lives toward lasting breast health behaviors.
	5.12 Immunothérapies
Affinity-Tuned CAR T Cells Slay Tumor Cells, Spare Normal Cells [GEN] The idea is to produce CAR T cells that are sufficiently insensitive to ignore normal cells, which are relatively target-sparse, and yet sensitive enough to latch onto cancer cells, which are relatively target-rich.
Could aspirin boost cancer immunotherapy? [Cancer Research UK] The scientists saw the same immunotherapy-boosting power of aspirin when mice were transplanted with bowel cancer cells: even though the immunotherapy didn’t have much effect by itself, the tumours shrank significantly in around a third of the animals treated with the combination.
Aspirin could hold the key to supercharged cancer immunotherapy [Cancer Research UK] Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell.
Aspirin could help boost cancer treatment, experts find [The Telegraph] The anti-inflammatory pain killer suppresses a cancer molecule that allows tumours to evade the body's immune defences, a study has found.
Scientists turn to aspirin to turbo-charge cancer immunotherapy [Reuters] Aspirin blocks PGE2 production and the researchers found that adding it to an immunotherapy treatment called anti-PD-1 substantially slowed the growth of bowel and melanoma cancers in mice when compared with treatment by immunotherapy alone.
	5.2.1 Pharma - Partenariats
MD Anderson and Cellectis announce pre-clinical and clinical alliance in cancer immunotherapy [MD Anderson Cancer Center] The alliance is aimed at developing novel cancer immunotherapies based on Cellectis’ allogeneic chimeric antigen receptor (CAR) platform.
MD Anderson adds Cellectis to a crush of immunotherapy collaborations [FierceBiotech] This particular partnership arrives as Cellectis is setting up studies for new drugs aimed at leukemia and myeloma. And while it's a few clinical steps behind leaders like Novartis, Juno and Kite, the biotech and its allies at MD Anderson believe they can close the gap quickly.
MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy [Cellectis] Cellectis, the gene editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, and The University of Texas MD Anderson Cancer Center have entered into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors.
	5.3 Traitements - FDA, EMA,...
AZ' NSCLC drug clears first hurdle to early access in the UK [Pharma Times] The Medicines and Healthcare Products Regulatory Agency has awarded the drug Promising Innovative Medicine status as a treatment for locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC.
	5.3.4 Traitements - AMM (FDA, EMA)
Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma [Novartis] As the first HDAC inhibitor approved in the EU for multiple myeloma, Farydak may help reset key cell function in multiple myeloma through epigenetic activity.
	5.4 Traitements - Economie
Bankrupted by cancer: Why “cost” is an important criterion in our review process [HealthNewsReview] Mentioning cost in any discussion of new cancer therapies is a critical step toward raising public awareness.
Life-extending cancer drugs to be axed by NHS [The Guardian] Among the drugs NHS England is expected to “de-list” from the Cancer Drugs Fund is Kadcyla, which holds the record as the most expensive cancer drug brought to market, costing £90,000 annually per patient.
	5.5 ASCO
2015 Palliative Care in Oncology Press Program to Feature New Tools, Insights for the Delivery of High-Quality Palliative Care [ASCO] Abstracts will explore palliative care across the entire cancer continuum, both throughout treatment and at the end of life.
	6. Lutte contre les cancers
Targeting Cancer: A Basketful of Hope [DNA Science Blog] When people announce precision medicine on TV, that’s wrong. I’d never do it. We need to take it seriously and be humble and take a step-by-step approach. At Memorial we are conducting 25 to 30 basket trials, and we offer them to the patients. But this is a work-in-progress. We have a duty to not oversell this to the public.
NICE consults on draft guideline on Upper aerodigestive tract cancers [NICE] The new draft guideline includes recommendations on the best tests to help diagnose these types of cancers earlier, which treatments are most suitable at each stage and what information should be provided to people throughout their treatment.
	6.10 Politiques
US agencies plan research-ethics overhaul [Nature News & Comment] Long-awaited revision proposed for regulations governing studies of human subjects.
	6.5 Médecines alternatives
Cancer quackery going the distance [Respectful Insolence] Where Sargeant goes off the rails (well, one of many places) is when he attributes the cause of those mutations leading to cancer to stress due to suppressing emotion or personal trauma. In this, he sounds like a mad, mutated version of the German New Medicine.
	6.6 Publications
Why I’m not jumping on the ORCID bandwagon [opiniomics] I have used both PURE and ORCID and let me tell you – PURE makes ORCID look like a 5yr old’s summer project. They are not even comparable, so I don’t know why I am trying. Whilst PURE is a Ferrari, ORCID is a push-bike with only one wheel and the chain is broken.
	6.7 DMP, Big Data & applis
Salesforce.com charges in to healthcare with Health Cloud — interview with CMO Joshua Newman [Health Business Blog] Today’s health systems need to make the shift from revenue cycle management and electronic health records, to building stronger patient relationships. With our open API, metadata-driven platform, providers can use Salesforce as an engagement layer on top of their legacy EMR systems.